GB0911042D0 - Treatment of tumorigenic cells in solid tumours - Google Patents

Treatment of tumorigenic cells in solid tumours

Info

Publication number
GB0911042D0
GB0911042D0 GBGB0911042.0A GB0911042A GB0911042D0 GB 0911042 D0 GB0911042 D0 GB 0911042D0 GB 0911042 A GB0911042 A GB 0911042A GB 0911042 D0 GB0911042 D0 GB 0911042D0
Authority
GB
United Kingdom
Prior art keywords
treatment
solid tumours
tumorigenic cells
tumorigenic
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0911042.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Superiore di Sanita ISS
Original Assignee
Istituto Superiore di Sanita ISS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore di Sanita ISS filed Critical Istituto Superiore di Sanita ISS
Priority to GBGB0911042.0A priority Critical patent/GB0911042D0/en
Publication of GB0911042D0 publication Critical patent/GB0911042D0/en
Priority to EP10737760A priority patent/EP2445500A1/en
Priority to PCT/EP2010/004119 priority patent/WO2010149394A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0911042.0A 2009-06-25 2009-06-25 Treatment of tumorigenic cells in solid tumours Ceased GB0911042D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0911042.0A GB0911042D0 (en) 2009-06-25 2009-06-25 Treatment of tumorigenic cells in solid tumours
EP10737760A EP2445500A1 (en) 2009-06-25 2010-06-25 Combination treatment op a g2 checkpoint inhibitor (sb-218078) and a chemotherapeutic agent for tumorigenic cells in solid tumors
PCT/EP2010/004119 WO2010149394A1 (en) 2009-06-25 2010-06-25 Combination treatment op a g2 checkpoint inhibitor (sb-218078) and a chemotherapeutic agent for tumorigenic cells in solid tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0911042.0A GB0911042D0 (en) 2009-06-25 2009-06-25 Treatment of tumorigenic cells in solid tumours

Publications (1)

Publication Number Publication Date
GB0911042D0 true GB0911042D0 (en) 2009-08-12

Family

ID=41008276

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0911042.0A Ceased GB0911042D0 (en) 2009-06-25 2009-06-25 Treatment of tumorigenic cells in solid tumours

Country Status (3)

Country Link
EP (1) EP2445500A1 (en)
GB (1) GB0911042D0 (en)
WO (1) WO2010149394A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
KR20170063722A (en) 2014-10-03 2017-06-08 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response
AU2016219379B2 (en) 2015-02-10 2020-11-26 Ohio State Innovation Foundation Chlamydia-activated B cell platforms and methods thereof
JP7086000B2 (en) 2015-11-10 2022-06-17 オハイオ・ステート・イノヴェーション・ファウンデーション Methods and compositions for accelerating humoral affinity
JP7146732B2 (en) 2016-07-13 2022-10-04 オハイオ ステート イノベーション ファウンデーション Platforms and methods for optimizing host antigen presentation and host anti-tumor and anti-pathogen immunity
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002526450A (en) * 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション CHK1 kinase inhibitor
CN100584840C (en) 2004-01-05 2010-01-27 阿斯利康(瑞典)有限公司 Substituted heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
EP2445500A1 (en) 2012-05-02
WO2010149394A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
GB0911042D0 (en) Treatment of tumorigenic cells in solid tumours
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
IL218575A0 (en) Treatment of cancer
ZA201008392B (en) Treatment of pluripotent cells
HK1175476A1 (en) Cancer treatment
SG10201508495VA (en) Combination treatment of cancer
ZA201208413B (en) Skin treatment composition
ZA201307036B (en) Treatment of solid tumours
AP3480A (en) Phosphaplatins and their use for treatment of cancers
IL222958A0 (en) Cancer treatment
EP2404592A4 (en) Hair treatment composition
ZA201202213B (en) Treatment of minerals
ZA201105125B (en) Hair treatment composition
PL388252A1 (en) Combination therapy of colorectal cancer
ZA201208568B (en) Skin treatment composition
ZA201201116B (en) Hair treatment composition
ZA201202657B (en) Use of the sparc microenvironment signature in the treatment of cancer
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB0916686D0 (en) Treatment of cancer
EP2552443A4 (en) Improved treatment of renal cell carcinoma
IL220241A0 (en) Use of transferrin in treatment of beta-thalassemias
GB201002499D0 (en) Treatment of tumours
GB0921757D0 (en) Treatment of cancer
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201017356D0 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)